NF1 — Neurofibromin 1

NF1 — Neurofibromin 1

Introduction

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Neurofibromin 1</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>NF1</td></tr>
<tr><td><strong>Full Name</strong></td><td>Neurofibromin 1</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>17q11.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[4760](https://www.ncbi.nlm.nih.gov/gene/4760)</td></tr>
<tr><td><strong>OMIM</strong></td><td>613113</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>[ENSG00000196712](https://www.ensembl.org/Homo_sapiens/ENSG00000196712)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P21359](https://www.uniprot.org/uniprot/P21359)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Neurofibromatosis Type 1, Cognitive Impairment, Gliomas, Learning Disabilities, Alzheimer's Disease, Parkinson's Disease</td></tr>
</table>
</div>

NF1 (Neurofibromin 1) encodes a large tumor suppressor protein that negatively regulates the Ras signaling pathway. Originally identified as the gene mutated in Neurofibromatosis Type 1 (NF1), neurofibromin is now recognized as a critical regulator of neuronal function, synaptic plasticity, and cellular homeostasis throughout the nervous system[@ballester1990][@gutmann2012].

Overview

NF1 — Neurofibromin 1

Introduction

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Neurofibromin 1</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>NF1</td></tr>
<tr><td><strong>Full Name</strong></td><td>Neurofibromin 1</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>17q11.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[4760](https://www.ncbi.nlm.nih.gov/gene/4760)</td></tr>
<tr><td><strong>OMIM</strong></td><td>613113</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>[ENSG00000196712](https://www.ensembl.org/Homo_sapiens/ENSG00000196712)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P21359](https://www.uniprot.org/uniprot/P21359)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Neurofibromatosis Type 1, Cognitive Impairment, Gliomas, Learning Disabilities, Alzheimer's Disease, Parkinson's Disease</td></tr>
</table>
</div>

NF1 (Neurofibromin 1) encodes a large tumor suppressor protein that negatively regulates the Ras signaling pathway. Originally identified as the gene mutated in Neurofibromatosis Type 1 (NF1), neurofibromin is now recognized as a critical regulator of neuronal function, synaptic plasticity, and cellular homeostasis throughout the nervous system[@ballester1990][@gutmann2012].

Overview

NF1 Gene is a tumor suppressor gene that plays essential roles in the nervous system. Beyond its well-established role in tumor suppression, neurofibromin is increasingly recognized for its functions in:

• Neuronal development: Regulation of neural progenitor proliferation and differentiation
• Synaptic plasticity: Modulation of learning, memory, and cognitive function
• Myelination: Control of oligodendrocyte differentiation and myelin formation
• Cellular homeostasis: Regulation of Ras/MAPK signaling, cAMP levels, and mitochondrial function

Gene Structure and Protein

The NF1 gene spans approximately 350 kb on chromosome 17q11.2 and contains 60 exons. It encodes neurofibromin, a 2,818 amino acid protein with a molecular weight of ~327 kDa. The protein contains several functional domains:

Key Domains

| Domain | Location | Function |
|--------|----------|----------|
| GAP-related domain (GRD) | Central region | Accelerates Ras GTP hydrolysis |
| C-terminal domain | C-terminus | Protein-protein interactions |
| Tubulin-binding domain | N-terminus | Cytoskeletal regulation |
| NLS motifs | Scattered | Nuclear localization |

The GAP-related domain (GRD) is the most functionally critical region, comprising residues 1,198-1,538. This domain accelerates GTP hydrolysis on H-Ras, N-Ras, and K-Ras proteins by approximately 1,000-fold, converting active Ras-GTP to inactive Ras-GDP. Approximately 50% of NF1 disease-causing mutations affect the GRD[@ballester1990][@gutmann2012].

Biological Functions

Ras/MAPK Signaling Regulation

Neurofibromin is the primary negative regulator of Ras signaling in the nervous system. Under normal conditions, neurofibromin maintains Ras signaling at appropriate levels by promoting GTP hydrolysis. Loss of neurofibromin function leads to:

• Constitutive Ras activation
• Increased MAPK/ERK signaling
• Dysregulated cell proliferation
• Altered neuronal differentiation

Synaptic Plasticity and Learning

Neurofibromin plays a critical role in synaptic plasticity, learning, and memory. Studies in mouse models have demonstrated that:

• NF1 haploinsufficiency impairs hippocampal long-term potentiation (LTP)
• Loss of NF1 affects learning and memory in contextual fear conditioning
• NF1 regulates cAMP signaling at synapses
• Neurofibromin modulates NMDA receptor function

Myelination

In the central nervous system, neurofibromin regulates oligodendrocyte differentiation and myelination:

• NF1 expression increases during oligodendrocyte maturation
• Loss of NF1 impairs myelination in the corpus callosum
• NF1 haploinsufficiency leads to decreased myelin thickness
• The function involves regulation of PDGF signaling

Mitochondrial Function

Recent research has revealed that neurofibromin localizes to mitochondria and regulates mitochondrial function:

• NF1 deficiency leads to mitochondrial dysfunction
• Altered mitophagy in NF1-deficient neurons
• Increased oxidative stress
• Impaired ATP production

Expression Pattern

Neurofibromin is widely expressed in the nervous system:

• Neurons: High expression in pyramidal neurons of the hippocampus and cortex, cerebellar Purkinje cells, and dopaminergic neurons of the substantia nigra
• Astrocytes: Moderate expression, with increased expression in reactive astrocytes
• Oligodendrocytes: High expression during active myelination
• Microglia: Lower basal expression, increases with activation

• Neuronal activity
• Growth factors (NGF, BDNF, PDGF)
• cAMP levels
• Developmental timing

Disease Associations

Neurofibromatosis Type 1

Neurofibromatosis Type 1 (NF1) is one of the most common autosomal dominant genetic disorders, affecting approximately 1 in 3,000 individuals. Caused by heterozygous loss-of-function mutations in the NF1 gene, NF1 is characterized by:

• Café-au-lait spots
• Neurofibromas (cutaneous and plexiform)
• Lisch iris hamartomas
• Optic pathway gliomas
• Cognitive impairment
• Skeletal abnormalities

Alzheimer's Disease

Emerging evidence links NF1 dysfunction to Alzheimer's disease pathogenesis:

NF1 haploinsufficiency promotes tau pathology: Recent studies demonstrate that reduced neurofibromin expression accelerates tau phosphorylation and aggregation in cellular and mouse models. NF1 deficiency enhances GSK-3β activity, a key kinase in tau phosphorylation, leading to increased NFT formation[@kim2024].

Neuroinflammation: NF1-deficient astrocytes show increased pro-inflammatory cytokine production, contributing to chronic neuroinflammation in AD models. This involves dysregulated NF-κB signaling and enhanced microglial activation[@gottardi2024].

Synaptic dysfunction: Neurofibromin loss disrupts synaptic plasticity mechanisms essential for learning and memory. In AD models, NF1 deficiency exacerbates amyloid-β-induced synaptic deficits[@harris2020].

Therapeutic implications: MEK inhibitors (which block downstream Ras signaling) have shown promise in rescuing cognitive deficits in NF1 deficiency models and may have utility in AD treatment. However, the complex role of Ras signaling in different cell types requires careful consideration[@zhou2022].

Parkinson's Disease

NF1 has been implicated in Parkinson's disease through several mechanisms:

Dopaminergic neuron vulnerability: NF1 regulates Ras signaling in dopaminergic neurons of the substantia nigra pars compacta. Altered NF1 expression may contribute to the selective vulnerability of these neurons in PD[@chen2021].

Mitochondrial dysfunction: Given the established role of mitochondrial dysfunction in PD, the mitochondrial regulatory function of neurofibromin is particularly relevant. NF1 deficiency leads to impaired mitophagy and increased oxidative stress in dopaminergic neurons[@moruno2023].

α-Synuclein interaction: Preliminary studies suggest that NF1 may interact with α-synuclein aggregation pathways, though this requires further investigation.

Gliomas

NF1 mutations are associated with multiple glioma types:

| Glioma Type | NF1 Mutation Frequency | Clinical Features |
|-------------|----------------------|-------------------|
| Optic pathway glioma | ~50% in NF1 patients | Visual impairment |
| Pilocytic astrocytoma | 10-15% sporadic | Indolent course |
| Diffuse midline glioma | Rare | Poor prognosis |
| Glioblastoma | ~10-15% in adults | Aggressive |

Sporadic gliomas with NF1 mutations often have distinct molecular features and may respond differently to therapy. NF1 loss in glioma stem cells promotes tumor initiation and maintenance[@barnholtz2019][@abdulkadir2018].

Therapeutic Implications

MEK Inhibitors

The most established targeted therapy for NF1-related conditions is MEK inhibition:

• Selumetinib: FDA-approved for pediatric NF1-related plexiform neurofibromas; shows 70% response rate
• Trametinib: Being evaluated in clinical trials for NF1-associated tumors
• Cobimetinib: Similar MEK inhibitor under investigation

Statins

Statins (HMG-CoA reductase inhibitors) have been investigated for NF1 cognitive deficits:

• Rationale: Inhibit Ras prenylation, reducing Ras membrane localization and signaling
• Evidence: Mixed results in clinical trials; some studies show cognitive benefit[@krab2008]
• Limitations: Peripheral vs. central effects; dose-dependent outcomes

cAMP Modulators

Given the role of cAMP dysregulation in NF1 cognitive deficits:

• PDE4 inhibitors: Roflumilast and similar compounds under investigation
• cAMP analogs: Experimental approaches to enhance synaptic plasticity
• Combination therapy: MEK inhibitors with cAMP modulators showing promise in mouse models

Mitochondrial Protection

Given the role of NF1 in mitochondrial function:

• Antioxidants: CoQ10, vitamin E, and related compounds
• Mitophagy modulators: Enhancing clearance of damaged mitochondria
• Metabolic support: Supporting neuronal energy requirements

Model Systems

Mouse Models

Several NF1 mouse models have been developed:

| Model | Mutation | Phenotype |
|-------|----------|-----------|
| Nf1+/− | Heterozygous knockout | Learning deficits, tumor predisposition |
| Nf1fl/−; Nes-Cre | Neural progenitor knockout | Brain developmental abnormalities |
| Nf1fl/−; GFAP-Cre | Astrocyte knockout | Astrocyte dysfunction, altered behavior |
| Nf1fl/−; Olig1-Cre | Oligodendrocyte knockout | Myelination defects |

These models have been crucial for understanding NF1 functions and testing therapeutic approaches[@robinson2015].

Cellular Models

• iPSC-derived neurons: Patient-specific neurons carrying NF1 mutations
• Astrocyte cultures: Primary astrocytes from Nf1-deficient mice
• Organoid models: 3D brain organoids modeling NF1 deficiency

NF1 and Neuroinflammation

Neuroinflammation is a hallmark of neurodegenerative diseases, and NF1 plays a complex role in regulating inflammatory responses:

Astrocyte-specific effects: NF1-deficient astrocytes show a pro-inflammatory phenotype characterized by:

• Increased IL-1β, IL-6, and TNF-α production
• Enhanced NF-κB activation
• Chemokine secretion recruiting microglia
• Reactive astrogliosis

Therapeutic implications: Anti-inflammatory therapies may be particularly relevant for patients with NF1 deficiency.

NF1 and GSK-3β Signaling

Glycogen synthase kinase-3 beta (GSK-3β) is a key downstream effector of Ras/MAPK signaling and plays a central role in tau phosphorylation. Neurofibromin deficiency leads to increased GSK-3β activity through multiple mechanisms:

• Direct regulation: NF1 interacts with GSK-3β and modulates its activity
• PI3K/AKT pathway: NF1 loss affects AKT signaling, relieving GSK-3β inhibition
• Wnt pathway crosstalk: NF1 influences β-catenin degradation through GSK-3β

NF1 Polymorphisms and Neurodegenerative Disease Risk

Alzheimer's Disease

Genome-wide association studies (GWAS) have identified NF1 variants associated with AD risk:

• SNPs in NF1 locus: Certain single nucleotide polymorphisms show modest association with AD risk
• Expression quantitative trait loci (eQTLs): Variants affecting NF1 expression in brain

Parkinson's Disease

Similarly, NF1 variants have been associated with PD risk:

• Rare variants: Loss-of-function variants may increase PD susceptibility
• Gene-environment interactions: NF1 variants may modify risk from environmental toxins

Clinical Features of NF1

Diagnostic Criteria (NIH)

Two or more of the following:

Neuropsychological Profile

Individuals with NF1 commonly exhibit:

• Learning disabilities (50-80%)
• Attention deficit/hyperactivity disorder (30-50%)
• Language deficits
• Visual-spatial impairments
• Executive function deficits
• Reduced IQ (mean ~10 points below population mean)

Challenges in NF1-Targeted Therapy

Several challenges remain in developing effective NF1-targeted therapies:

Future Directions

Gene Therapy Advances

• CRISPR/Cas9: Precise correction of NF1 mutations
• Base editing: Single-nucleotide corrections without double-strand breaks
• Delivery optimization: Improved AAV capsids for brain targeting

Small Molecule Development

• Next-generation MEK inhibitors: Improved brain penetration and safety
• Ras inhibitors: Direct targeting of activated Ras
• Combination therapies: Multi-target approaches

Clinical Trial Design

• Basket trials: Group patients by molecular alterations rather than diagnosis
• Adaptive designs: Modify trials based on interim results
• Long-term follow-up: Understand durability of treatment effects

Key Publications

See Also

• [Neurofibromatosis Type 1](/diseases/neurofibromatosis-type-1)
• [NF1 Protein](/proteins/nf1-protein)
• [Ras Signaling Pathway](/mechanisms/ras-mapk-signaling)
• [MEK Inhibitors](/treatments/mek-inhibitors)
• [Alzheimer's Disease Mechanisms](/mechanisms/alzheimers-pathogenesis)
• [Parkinson's Disease Mechanisms](/mechanisms/parkinsons-pathogenesis)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Myelination](/mechanisms/myelination)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

External Links

• [NCBI Gene: NF1](https://www.ncbi.nlm.nih.gov/gene/4760)
• [UniProt: P21359](https://www.uniprot.org/uniprot/P21359)
• [OMIM: 613113](https://www.omim.org/entry/613113)
• [Ensembl: ENSG00000196712](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196712)
• [Children's Tumor Foundation](https://www.ctf.org/) - NF patient organization
• [NF1 Registry](https://nf1registry.org/) - Patient registry

References

Pathway Diagram

The following diagram shows the key molecular relationships involving nf1 discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving NF1 — Neurofibromin 1 discovered through SciDEX knowledge graph analysis: